Eiger BioPharmaceuticals2018-03-13T10:47:27+00:00

IN THE NEWS

Eiger BioPharmaceuticals to Participate in Investor Conferences

September 25th, 2018|

Eiger BioPharmaceuticals to Participate in Investor Conferences PALO ALTO, Calif., September 25, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present at two investor conferences in October in New York City. Cantor Fitzgerald 4th Annual Healthcare Conference at the Intercontinental New York Barclay. Corporate presentation on October 1, 2018, 4:40 PM ET.  Eiger will host one-on-one meetings. Ladenburg Thalmann [...]

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018

September 24th, 2018|

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 D-LIVR Study: First-Ever Registration Study for Chronic HDV Infection PALO ALTO, Calif., September 24, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the receipt of written guidance from the FDA, confirming concurrence on a pivotal trial design, including the primary endpoint for D-LIVR, the first-ever, registration study for Hepatitis [...]

Eiger Announces Positive Meeting with FDA on Progeria

September 4th, 2018|

Eiger Announces Positive Meeting with FDA on Progeria -  Company advancing plans to file NDA for Lonafarnib in ProgeriaPALO ALTO, Calif., September 4, 2018 – Today, Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a company focused on the development and commercialization of targeted therapies for rare diseases, announced it has received minutes from a pre-investigational new drug (pre-IND) meeting with the Division of Gastroenterology and Inborn Errors Products of the U.S. Food and Drug Administration (FDA) for lonafarnib in the treatment of [...]